Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 122 participants.
Also called NCT01564875
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 122 participants
- Registry
-
NCT01564875
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT01564875. Randomized; triple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2012-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia
- Acronym
- HM-SIM4
- Condition
- Chronic Kidney Disease
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Simvast CR
- Intervention (Drug)
- Zocor
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct01564875- Content hash
4511912afc9fc220d2a647a6b9bdad6879026196c596db0a5ee3e2973a243de5